Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage by Russell, A J et al.
Until recently, adrenocortical tumours were recognized clinically
only if they secreted excess hormone or demonstrated obvious
malignant behaviour. However, adrenocortical nodules of 2–3 cm
diameter may be found at autopsy in 1.5–8.7% (Lack et al, 1990)
of an unselected population. While some of these represent hyper-
plastic regenerative nodules adjacent to ischaemic atrophic change
(Dobbie, 1969; Sasano et al, 1971), many are neoplastic. With the
increasing use of sensitive scanning techniques, they are now
being identified when patients are investigated for other intra-
abdominal pathology. There is a therapeutic issue therefore of
whether to remove them or not, because of the risk of malignancy
(Prinz et al, 1982; Thompson and Cheung, 1987). Since carci-
nomas are on average larger than adenomas, at present larger
lesions are removed, while smaller ones are monitored. However,
in view of the extremely poor prognosis of adrenocortical carci-
noma with mortality up to 92% (Karakousis et al, 1985) it would
be important to develop markers of malignant potential which
could be applied to individual lesions at the earliest possible stage,
as even small lesions may be malignant (McNicol, 1992). This
might be made possible by identifying specific molecular genetic
events differentiating neoplastic from hyperplastic nodules and
indicating malignant potential.
The molecular pathogenesis of adrenocortical tumours is poorly
understood, and it is unclear whether there is an adenoma-
carcinoma sequence. The rarity of the tumour and the low level of
proliferation have made classical cytogenetic analysis difficult.
Demonstration of allelic loss on chromosomes 11p, 13q and 17p
(Henry et al, 1989; Yano et al, 1989) suggest that genes at these
loci may have a role in pathogenesis. Familial adrenocortical
cancer occurs in Beckwith–Wiedemann syndrome linked to 11p
15.5, and now known to be associated with paternal disomy for the
insulin-growth factor-II (IGF-II) gene (Weksberg et al, 1993). It
also occurs more frequently in association with the Li–Fraumeni
syndrome (Li and Fraumeni, 1969), associated with germline
mutations of the p53 gene, on 17p13 (Srivastava et al, 1990). The
demonstration of abnormal expression of IGF-II (Ilvesmaki et al,
1993) and p53 (Ohgaki et al, 1993; McNicol et al, 1997) in
sporadic adrenocortical carcinoma would support a role for these
proteins in tumorigenesis. The MEN-1 locus on chromosome 11q
is another possible site of interest (Skogsaid et al, 1992; Iida et al,
1995). In an attempt to identify other potential loci, Kjellman et al
(1996) have used comparative genomic hybridization (CGH) to
screen for chromosomal gain and loss in adrenocortical tumours.
Their data indicate that widespread changes can be found in carci-
noma, but are rare in adenoma.
We have chosen the alternative approach of interphase cyto-
genetics (Poddighe et al, 1992), where probes specific to indi-
vidual chromosomes are hybridized to paraffin sections. This has
the advantage of allowing the analysis of changes in chromosome
number in defined tumour cell populations (Murphy et al, 1995).
The aims were to define and compare chromosome imbalances in
a series of adrenocortical adenomas and carcinomas. This would
potentially permit us to identify loci of interest in tumour patho-
genesis and progression. The chromosomes selected for analysis
have previously been shown to be altered in other tumours.
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Summary The investigation of chromosomal aberrations in adrenocortical tumours has been limited by the difficulties of applying classical
cytogenetics to tumours with low levels of proliferation. We have therefore applied the technique of interphase cytogenetics to paraffin-embedded
archival specimens of 14 adrenocortical adenomas and 13 carcinomas. Hybridizations were performed using centromere-specific probes to
chromosomes 3, 4, 9, 17, 18 and X, which have been shown to be altered in other types of tumours. Chromosomal imbalance was defined on
the basis of changes in both chromosome index (CI) and signal distribution (SD). Where only one of these was altered, this was classified as a
tendency to gain or loss. On the basis of the analysis of optimal hybridizations, carcinomas showed gains in all chromosomes studied, five of nine
showing gains in multiple chromosomes. Gains were most common in chromosomes 3, 9 and, in particular X, eight of 11 showing gain, and one
a tendency to gain. Chromosomal gain was seen less commonly in adenomas, but again chromosomes 3, 9 and X were involved. Losses were
infrequent, only one carcinoma showing loss of chromosome 18, and adenomas showing a tendency to loss of chromosomes 4 (two cases), 17
(one case) and 18 (two cases). Our data suggest that changes in chromosomes 3, 9 and X are early events in adrenocortical tumorigenesis, and
that there is increasing chromosomal instability with tumour progression. © 1999 Cancer Research Campaign
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MATERIALS AND METHODS
Study population
Archival specimens were obtained from 14 adrenocortical
adenomas and 13 carcinomas. These had been classified on the
basis of clinical behaviour and on the histological criteria of van
Slooten et al (1985). All tissues were fixed in formalin and
embedded in paraffin wax. Normal human tonsil was used as
control. A diffusely hyperplastic adrenal gland removed surgically
from a patient with Cushing’s disease was also included as a
control.
Tissue section preparation (Murphy et al, 1995)
In brief, sections, 6-mm thick, were mounted on glass slides coated
in aminopropyltriethoxysilane. Before use, the slides were baked
at 65°C for 4–24 h. The tissue sections were dewaxed, rehydrated
and left to air dry. Sections were then digested with pepsin (0.4%
pepsin in 0.2 N hydrochloric acid) for 5–60 min and post-fixed for
10 min in tissue fixative (Streck Laboratories Inc., Omaha, NE,
USA). Sections were dehydrated for 2 ´ 3 min in 70% ethanol and
2 ´ 3 min in 100% ethanol, and left to air dry.
DNA probes
Chromosome-specific repetitive sequence probes for the following
loci were purchased from Oncor, Inc. (Gaithersburg, MD, USA):
D3Z1 (chromosome 3), D4Z1 (chromosome 4), D9Z1 (chromo-
some 9), D17Z1 (chromosome 17), D18Z1 (chromosome 18), and
DXZ1 (chromosome X). All commercial probes were ready
labelled with digoxigenin. Probes were diluted in a hybridization
mix consisting of 70% formamide, two times the standard concen-
tration of standard saline citrate (SSC) (1 ´ SSC is 0.15 M sodium
chloride and 0.015 M sodium citrate, pH 7), 500 mg ml–1 salmon
sperm DNA, and 10% dextran sulphate.
In situ hybridization
The probe in the hybridization mix and DNA in a tissue section
were denatured together using the Omnislide modular system
(Hybaid Ltd, London, UK) at 80°C for 5 min, then incubated at
37°C overnight. After hybridization, slides were washed twice in
50% formamide and 1 ´ SSC at 42°C for 10 min and twice
in 2 ´ SSC at 42°C for 10 min. Prior to immunocytochemical
detection, slides were blocked for 30 min in 4 ´ SSC-TB (4 ´ SSC,
0.05% Tween-20, and 0.5% Boehringer blocking agent;
Boehringer Mannheim, GmbH, Germany). Sites of hybridization
were detected using anti-digoxigenin alkaline phosphatase (AP)
Fab fragments (Boehringer Mannheim, GmbH, Germany) 1:300
dilution in 4 ´ SSC-TB, incubated for 45 min at room temperature.
Slides were washed in 4 ´ SSC, 0.5% Tween-20 for 20 min, then
rinsed in distilled water. The slides were then incubated in
NBT/BCIP solution (75 mg ml–1 nitroblue-tetrazolium (NBT),
50 mg ml–1 5-bromo-4-chloro-3-indolyl phosphate (BCIP)),
1.25 mM levamisole, 0.1 M Tris base, 0.1 M Tris–HCl, 0.1 mM
sodium chloride, 50 mM magnesium chloride overnight. Sites of
binding were identified as blue–black dots.
Quantitation of hybridization signals
Chromosome-specific centromeric probes were hybridized to
sections of adrenocortical adenoma and adrenocortical carcinoma
A B
Figure 1 (A) Adrenocortical carcinoma hybridized with centromeric probe for chromosome 18, showing two copies in most cells. (B) Adrenocortical carcinoma
hybridized with a centromeric probe for chromosome 9 showing three or more signals in many cells686 AJ Russell et al
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as shown in Figure 1. In order to obtain control values, centromere
copy numbers for the six chromosomes were assessed using tonsil
tissue. Hyperplastic adrenal gave a similar pattern of hybridiza-
tion. The evaluation and interpretation of ISH signals were carried
out as described by Hopman et al (1992) and Murphy et al (1995)
in which overlapping nuclei were not analysed, minor hybridiza-
tion signals identifiable by their low intensity and smaller spot area
compared with optimal control hybridizations were not counted.
Poor quality hybridizations were not analysed. Only nuclei with
the histological appearance of tumour cells were evaluated. For
each section, the number of signal spots per nucleus was recorded
for 200 nuclei. The hybridization data were analysed in two ways
to assess the degree of chromosome imbalance for each sample
and each chromosome. Firstly, the chromosome index (CI) was
calculated (Dhingra et al, 1994) by dividing the total number of
hybridization spots counted by the total number of nuclei counted.
The CI gives an average chromosome copy number and is there-
fore better suited to describe clonal changes within a tumour. The
CIs were calculated and plotted in Figure 2. The mean CI for
normal tissue was 1.42, and three standard deviations from the
mean gave values of 1.19 and 1.65. A tumour was defined as
polysomic for a given chromosome if its CI was greater than 1.65.
A tumour was defined as monosomic for a given chromosome if
its CI was less than 1.19. Changes for X chromosome were
analysed only in female cases.
The second method used to define chromosomal polysomy or
monosomy is the signal distribution. A tumour was described as
polysomic for a chromosome if the percentage of nuclei with more
than two hybridization sites was greater than 10% of the nuclei
counted. A tumour was described as monosomic for a chromo-
some if the percentage of nuclei with fewer than two hybridization
sites was greater than 60% of the nuclei counted. The analysis of
signal distribution can potentially detect relatively small popula-
tions of cells with numerical imbalances in chromosomes. These
criteria for both signal distribution and CI were based on published
estimates and previous experience of the technique and take into
account nuclear truncation (Hopman et al, 1992; Macoska et al,
1993; Baretton et al, 1994; Dinghra et al, 1994; Murphy et al,
1995).
Statistical analysis
Differences in chromosomal indices between adrenocortical
adenomas and normal and carcinomas and normal were compared
using the two-sided Mann–Whitney test with a priori level of
statistical significance set at P < 0.05.
RESULTS
In situ hybridization with chromosome-specific probes was carried
out on 14 adrenocortical adenomas and 13 carcinomas, although
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Figure 2 Scattergram showing distribution of chromosome index (CI) for chromosomes 3, 4, 9, 17, 18 and X in a series of adrenocortical carcinomas and
adenomas. The bars show the mean ± 3 s.d. of the controls. Values had to fall outwith these limits to be classed as gain or loss (ch = chromosome)
Table 1 Tumours showing evidence of chromosomal changes by signal
distribution
Chromosome number
3491 7 1 8 X
Carcinomas
Gain 4/9 4/9 5/10 3/9 2/9 5/6
Loss 1/9
Adenomas
Gain 2/6 1/10 3/14 1/12 2/10
Loss 2/10 1/12 2/9
Table 2 Chromosomal imbalances in adrenocortical carcinoma
Chromosome no. Loss Balanced Gain Total
3 0 6 3 (2) 9
4 0 7 2 (2) 9
90 5 5 1 0
17 0 6 3 9
18 1 6 2 9
X 0 3 8 (1) 11
Chromosomal imbalance was assessed on the combination of chromosome
index and signal distribution. Figures in brackets represent tumours showing
imbalance by either measurement alone.Interphase cytogenetics in adrenal cancer 687
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hybridization with all probes was not achieved on every tumour.
Figure 1A shows an example of a section of adrenocortical carci-
noma hybridized with a chomosome 18 probe showing two copies
per cell, while Figure 1B shows hybridization with a chomosome 9
probe showing three or more signals in many cells.
Chromosome index
The data are shown in Figure 2. Subjectively, there were frequent
gains in all chromosomes tested in adrenocortical carcinomas,
particularly for chromosomes 3, 9 and X. Losses were rarely
identified, only one showing loss of chromosome 18. The visual
changes were confirmed as significantly different from normal for
chromosome 3 (P = 0.002), chromosome 9 (P = 0.048), chromo-
some 17 (P = 0.025) and chromosome X (P < 0.001). Subjective
gains of chromosomes were seen in adenomas although less
frequently than in carcinomas. These were confirmed as different
from controls by statistical analysis in chromosome 3 (P = 0.003)
and chromosome X (P = 0.027).
Signal distribution
The data are shown in Table 1. Again, there appeared to be wide-
spread gains in adrenocortical carcinomas, chromosomes X, 9, 3
and 4 showing most marked changes with evidence of one loss of
chromosome 18. Adenomas showed fewer changes, with gains in
chromosomes 3, 9 and X more marked. Losses were more
commonly identified, again in 18, and also 4 and 17.
Assessment of chromosomal imbalance
The data in Figure 2 were combined with analysis of signal distri-
bution (Table 1) to assess chromosomal imbalance. The overall
data are shown in Tables 2 and 3. The figures in brackets show the
numbers of tumours with a trend to gain or loss where this was
seen in only one measurement. In general, the pattern follows that
seen in Figure 2. In carcinomas, gains were seen in all chromo-
somes tested. This was particularly prominent with chromosome
X, eight of 11 showing gain while a further carcinoma showed a
trend towards gain. No losses were identified, although one carci-
noma showed a trend towards loss of chromosome 18.
The most common aberration in adrenocortical adenomas was
gain of chromosome 9, two of 14 showing gain and a further
adenoma a trend towards gain. Gains of 3, 17 and X were also
seen. No losses were identified within the range of chromosomes
studied, although adenomas showed a trend towards loss of
chromosomes 4 (n = 2), 17 (n = 1) and 18 (n = 2).
Accumulation of chromosomal imbalances
Using the hybridization data for the six centromeric probes, each
tumour was analysed for the total number of chromosome imbal-
ances accumulated. Only those tumours which had been success-
fully tested for at least four of the six chromosome-specific
centromeric probes were taken into account. Tumours had to show
imbalance by both CI and signal distribution to be counted.
Table 4 shows greater accumulation of chromosomal imbalances
in adrenocortical carcinomas when compared to adrenocortical
adenomas.
DISCUSSION
This is the first study in which interphase cytogenetics has been
applied to define changes in chromosomal copy number in a series
of adrenocortical tumours. The technique is particularly useful
because of the low level of proliferation even in carcinomas,
rendering classical cytogenetic analysis difficult. A recent study
has also suggested that the cells which grow in culture may not be
representative of the total tumour population (Rosenberg et al,
1995). The chromosomes selected for study have been shown to
have imbalances in other tumours. Our analysis was stringent, in
that we defined chromosomal imbalance only if both CI and signal
distribution agreed. In addition, our cut-off points were strict, with
3 standard deviations (s.d.) on CI, compared to 2.58 s.d. used in
some other studies (Bulten et al, 1998) and a 60% level for cells
showing fewer than two hybridization sites to define loss on signal
distribution compared with 40% (Visscher et al, 1996) or 15%
(Sneige et al, 1996). We may thus have underestimated the extent
of gain or loss. Nevertheless, we demonstrated gains in all carci-
nomas, and in all chromosomes studied, although the pattern
varied somewhat with each tumour. These changes did not simply
reflect general changes in DNA ploidy, as the chromosome index
varied with the individual chromosomes. The gains in 9 (50%) and
X (72%) were particularly striking. Chromosomes 3, 4 and 17 also
showed a significant level of gain, particularly when tumours
showing a trend were considered. Where trends were recognized,
this was usually due to a gain detected by signal distribution and
not by CI. As discussed in Methods, this probably reflects the
presence of subclones within the tumour. Endoreduplication
followed by chromosomal loss and acquisition of structural
chromosomal abnormalities is thought to be a feature of tumour
development (Shackney et al, 1989; Cornelisse et al, 1992;
Devilee et al, 1994). This may result in the emergence of
subclones within a tumour which then progress through the
accumulation of mutant genes conferring growth advantage
(Shackney et al, 1989). These changes may reflect inactivation of
tumour suppressor genes due to point mutations and loss of
heterozygosity (LOH). Potential candidates include p53 on 17p
(McBride et al, 1986). We (McNicol et al, 1997) and others
Table 3 Chromosomal imbalances in adrenocortical adenoma
Chromosome no. Loss Balanced Gain Total
30 4 2 6
4 0 (2) 10 0 (1) 10
9 0 11 3 (1) 14
17 0 (1) 11 1 12
18 0 (2) 9 0 9
X0 9 2 1 1
Table 4 Accumulation of chromosomal imbalances
No. of chromosome imbalances
0 1 2 3 4 5 6 Total
No. of adenomas 5 3 0 0 1 0 0 9
No. of carcinomas 1 3 1 1 1 1 1 9
Chromosomal imbalance was assessed on the combination of chromosome
index and signal distribution. Figures in brackets represent tumours showing
imbalance by either measurement alone.(Ohgaki et al, 1993) have shown altered p53 expression, most
probably as a late event, in the development of adrenocortical
carcinoma. There are two candidate loci on chromosome 18;
DPC4 (deleted in pancreatic carcinoma) (Hahn et al, 1996) and
DCC (deleted in colon cancer) (Vogelstein et al, 1988).
Interestingly, the DPC4 gene encodes SMAD4, an important
intracellular component of the signalling pathway for the
inhibin/activin growth factor family (Kingsley, 1994). Recent
evidence from inhibin-a knockout mice (Matzuk et al, 1994) and
transgenic mice bearing an inhibin-a promoter Simian virus
40-T antigen transgene (Kananen et al, 1996) implicates the
inhibin/activin family in adrenocortical tumorigenesis, with a
suggestion that inhibin-a may be a tumour suppressor (Matzuk
et al, 1994). Further investigation using microsatellite markers
could be used to identify possible changes at these loci. There are
other genes of potential interest on the chromosomes showing
gains. Telomerase RNA which forms an integral part of the
telomerase protein–RNA complex involved in immortalization
is encoded by a gene on chromosome 3 (Feng et al, 1995).
Interestingly, a recent report on a small number of cases suggests
that the identification of telomerase activity in adrenocortical
tumours may indicate malignant potential (Hirano et al, 1998). On
chromosome 9, p16 is a candidate (Kamb et al, 1994). On
chromosome X there is the DAX-1 gene, which is important in the
differentiation and regulation of steroidogenic tissues (Guo et al,
1996).
Direct comparisons are not possible between the results of
interphase cytogenetic studies and CGH (Ried, 1998). Using the
alphoid repeat centromeric probes fine mapping of changes cannot
be achieved. However, the CGH study on adrenocortical tumours
also indicated widespread aberration in carcinoma (Kjellman et al,
1996), with gains and losses of all chromosomes, including those
which we examined. Their study indicated that the extent of
change increased with tumour size. We were unable to perform
such an analysis because of lack of information on tumour size in
our cases.
Our study suggests that chromosomal imbalance is much less
common in adenoma than in carcinoma and that changes in
chromosomes 3, 9 and X may occur at an early stage. The identifi-
cation of changes only on signal distribution would suggest that
clonal evolution is taking place. Common patterns seen in
adenomas and carcinomas and the accumulation of chromosomal
imbalances with tumour progression support the existence of an
adenoma–carcinoma sequence. One adenoma showed multiple
gains: this was a 13-year-old girl with a virilizing tumour who was
disease-free after 12 years of follow-up. Whether this reflects the
efficacy of surgery in this case or the lack of a critical step in
tumour progression is unknown.
The widespread abnormalities defined in our study are therefore
in keeping with the results of CGH which indicate that genetic
aberrations are common in adrenocortical cancer. This would
inevitably lead to major alterations in regulatory pathways and
may help explain the aggressive nature and resistance to therapy of
this tumour.
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